Therapeutically Targeting The Major Genetic Risk Factor Of Alzheimer’s Disease
Funder
National Health and Medical Research Council
Funding Amount
$530,069.00
Summary
The second greatest risk factor for Alzheimer’s disease (after age) is genetic variation in a protein called APOE, however it is unknown why APOE increases the risk of disease. We have new clinical and laboratory evidence that APOE incresase risk of Alzheimer’s disease by manipulating iron pathways in the brain. We plan to examine these pathways and apply a new theraputic we have developed that targets these pathways in animal models of Alzheimer’s disease.
Altered Myelin Sphingolipid Homeostasis In Alzheimer's Disease
Funder
National Health and Medical Research Council
Funding Amount
$629,532.00
Summary
Alzheimer’s Disease (AD) is the most common form of dementia, and its incidence is rising as the population ages. This project will provide a detailed analysis and explanation for the loss of particular lipid (fat) molecules that are essential for myelin integrity, in the brains of AD patients. Myelin is the insulating layer that surrounds brain cells, facilitating the transmission of electrical signals. This research will improve our understanding of how brain functions are impaired in AD.
Isoform-dependent ApoE Processing By Human Induced Pluripotent Stem Cells. A Novel Pathway Linking APOE Genotype And Alzheimer’s Disease Risk.
Funder
National Health and Medical Research Council
Funding Amount
$429,495.00
Summary
We recently discovered that a protein called apoE is cleaved in the brain to generate a small fragment that may have neuroprotective properties. We also discovered that human induced pluripotent stem cell (iPSC)-derived neurons produce apoE fragments identical to those in the brain. We will now characterise iPSC apoE and assess its neuroprotective properties. This will resolve the basis for the association of apoE with AD risk and potentially provide a new target for AD treatment.
Restoring Neuroprotective Sphingosine 1-phosphate Signalling In Alzheimer’s Disease
Funder
National Health and Medical Research Council
Funding Amount
$857,656.00
Summary
Our research team has recently shown that a vital signalling lipid called S1P is lost from the brains of people who are in the early stages of developing Alzheimer's Disease. S1P protects brain cells against toxic insults that cause Alzheimer's Disease. This project will investigate how loss of S1P sensitizes people to the development of Alzheimer’s Disease, and the effectiveness of clinical drugs that restore S1P signals in protecting against Alzheimer’s Disease and restoring brain function.